An Open-label, Single-arm, Multi-centre, Long-term Extension Trial to Evaluate the Safety and Efficacy of Tralokinumab in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Clinical Trials
Latest Information Update: 14 Mar 2025
At a glance
- Drugs Tralokinumab (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Registrational
- Acronyms ECZTEND
- Sponsors LEO Pharma
Most Recent Events
- 25 Oct 2024 According to a Leo Pharma media release, the ECZTEND abstract and poster will also be published in the peer-reviewed journal Skin at a later date.
- 25 Oct 2024 According to a Leo Pharma media release, data from the study were presented in a poster at the Fall Clinical Dermatology Conference in Las Vegas, Nevada, from October 24-27, 2024.
- 25 Oct 2024 Results presented in the Leo Pharma Media Release.